Unlocking the Full Potential of GLP-1 Investments
How Avalon improves GLP-1 impact by refining eligibility criteria, addressing cardiometabolic risk, and reducing waste from misaligned utilization.
GLP-1 receptor agonists are redefining care for cardiometabolic conditions.
However, legacy approaches to patient eligibility haven’t kept pace. Health plans are under pressure to manage rising costs, prove value, and ensure equitable access—yet outdated targeting models create significant barriers:
Misses key indicators of cardiometabolic risk.
Prioritizes low-risk patients who may not benefit clinically.
Leaves high-risk patients without access to life-changing therapies.
Low-risk, non-diabetic patients are
14x
more likely to receive GLP-1 therapy than high-risk counterparts.
Individuals with <5% cardiovascular event risk are
more likely
to receive therapy than those with >10% risk.
These disparities lead to misallocated spending, worsened health outcomes, and diminished ROI.
Avalon’s Approach
Our next-generation framework replaces static metrics with dynamic, real-time lab data and predictive analytics to guide high-value coverage decisions.
Why this Matters
The GLP-1 market will continue to grow, but coverage decisions made today will define outcomes for the next decade. By embracing a new model, payers can lead the industry toward a data-driven, equity-focused, and cost-effective approach to managing cardiometabolic disease.
Let Avalon help you simplify GLP-1 therapy management.